Human Growth Hormone (hGH) Market Report

Human Growth Hormone (hGH) Market Analysis By Application (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, SGA), By Region, And Segment Forecasts, 2018 - 2025

  • Published Date: Dec, 2017
  • Base Year for Estimate: 2016
  • Report ID: GVR-2-68038-057-6
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2016
  • Number of Pages: 100

Industry Insights

The global human growth hormone market size was valued at USD 3.7 billion in 2016 and is projected to grow at a CAGR of 7.5% over the forecast period. Investment by market players, the presence of strong pipeline, and rising affordability of hormone therapy in the emerging countries are likely to drive growth.

Widening application of growth hormone (GH) and increasing awareness about the effectivity of GH in short stature are the major reasons for the growth of the market. For instance, according to results from the latest Partnership Attitude Tracking Study (PATS), usage of synthetic human growth hormone by teenagers increased by 120% from 2012 to 2013.

U.S. human growth hormone market

Technological advancements such as the development of recombinant human growth hormone (rhGH) by market players is further expected to boost the market growth in coming years. Major rhGH used in the U.S. are Norditropin, Humatrope, Nutropin-AQ, Genotropin, Saizen, Tev-tropin, and Omnitrope.

Many companies are investing in research & development of long-acting hormonal therapy with lesser adverse effects. Furthermore, companies made an investment to increase the manufacturing capacity. For instance, Novo Nordisk invested multi-million dollar in Lebanon to increase supply in a rural community in 2016. This site will produce medicines to treat hemophilia and growth disorders.

Application Insights

By application, the market has been segmented into growth hormone deficiency, Idiopathic Short Stature (ISS), Turner syndrome, Prader-Willi syndrome, Small for Gestational Age (SGA), and others. In 2016, growth hormone deficiency segment accounted for the largest market share and is expected to maintain its dominance during the forecast period.

Adult Growth Hormone Deficiency (AGHD) is increasing due to several factors such as pituitary tumors, neuropsychiatric-cognitive, neuromuscular, cardiovascular, skeletal abnormalities and metabolic abnormalities. Most of these disorders can be reversed with growth hormone therapy. It is expected that in the adult UK population at any given time, about one in every 10,000 people will have an adult onset growth hormone deficiency.

Turner syndrome accounted for the second largest share of the GH market in 2016 due to their ability to treat delayed physical as well as sexual development. The U.S. FDA approved hGH as standard treatment for Turner syndrome in 1996. Common brands of GH used to treat Turner syndrome include Humatrope, Genotropin, and Nutropin.

Creutzfeldt-Jakob disease, SHOX gene haploinsufficiency, chronic renal insufficiency, skeletal dysplasia, Down syndrome, and Noonan syndrome are other indications for which growth hormone therapy is approved in various countries. Expansion of indications is expected to boost the other segment market growth in coming years.

Regional Insights

North America dominated the global market in 2016 and accounted for around 48.0%. This can be attributed to affordability for costly medicine, the presence of pipeline, local presence of market players, and commercialization of GH by the U.S.FDA since last few years.

Global human growth hormone market

Asia Pacific is anticipated to witness the fastest growth during the forecast period as the demand for GH is rising in the emerging countries for the past few years. Japan, Australia, China, and India are the major contributing countries in the region. Investment by market players in the region due to the growing demand is one of the major factors for the market growth. For instance, in March 2017, Novo Nordisk initiated phase 3 clinical trial of somapacitan (NNC0195-0092) for AGHD using Norditropin as comparator in Japan.

Presence of large patient pool in the Asia Pacific region and increasing awareness about the effectivity of the GH is anticipated to boost the market in coming years. Japan accounted for the largest share of the market in 2016 due to high cost of the GH and local presence of market players.

Competitive Insights

The hGH market is consolidated in nature. Major players operating in the market are Eli Lilly and Company, Ferring Holding SA, Genentech, Inc., Merck & Co., Inc.; Novo Nordisk, Pfizer, Inc.; Sandoz International GmbH, and Ipsen.

Investment for the development of effective & long-acting products with lesser adverse effects and improving geographic penetration through partnerships and collaborations are the key strategies adopted by the companies to increase their market share. For instance, in December 2014, Pfizer entered into an agreement with OPKO for development and commercialization of human growth hormone hGH-CTP for treatments in children and adults.

In January 2015, Novo Nordisk received U.S. FDA approval for Norditropin FlexPro, an injection pen for patients with disorders related to growth hormones.

Report Scope

Attribute

Details

Base year for estimation

2016

Actual estimates/Historical data

2014 - 2016

Forecast period

2017 - 2025

Market representation                                                

Revenue in USD Million and CAGR from 2017 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Country scope

U.S., Canada, Germany, U.K., China, Japan, Brazil, Mexico, South Africa

Report coverage             

Revenue forecast, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization


Segments Covered in the Report

This report forecasts revenue growth at global, regional, & country levels and provides an analysis on industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global Human Growth hormone market on the basis of application and region:

  • Application (Revenue, USD Million, 2014 - 2025)

    • Growth Hormone Deficiency

    • Turner Syndrome

    • Idiopathic Short Stature

    • Prader-Willi Syndrome

    • Small for Gestational Age

    • Others 

  • Regional Outlook (Revenue, USD Million, 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

    • Asia Pacific

      • Japan

      • China

    • Latin America

      • Brazil

      • Mexico

    • Middle East & Africa

      • South Africa

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $5,950
Multi User (2-5) - $7,950
BI Library Access - $9,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified